immunotherapy News
-
Patent protection for innovative technology-platform
BlueSky Immunotherapies has expanded and secured its intellectual property portfolio. The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform. Corresponding patents were recently granted in (EP 3063273), USA (US 10480013), and China (CN 2019112100112140) ...
-
Phase 1 clinical trial: delNS-based immunotherapy against HPV 16
Viennese biotechnology company BlueSky Immunotherapies GmbH (Ltd.) has completed the second cohort of its phase 1 clinical trial against HPV 16. The results: Intradermal administration has been confirmed to be safe and well tolerated. Preliminary indications of efficacy were observed. Their proprietary innovative delNS technology for interferon-inducing viral vectors is a next-generation ...
-
Filtricine research on scientific conference for cancer treatment
At the AACR-NCI-EORTC conference for molecular targets (#Targets19) at Boston, we presented our latest preclinical research on treating colon cancer and boosting anti-PD-1 immunotherapy with our “targeted nutrient deprivation” ...
-
Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions was published in the Bulletin des Annonces Légales ...
By Transgene
-
Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants
Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. This funding will allow the immunotherapy currently in pre-clinical studies to progress to Phase II clinical trials. In ...
-
Sarcoids in horses: Next milestone in cancer therapy
We are glad to announce that scientists from our biotechnology company BlueSky Immunotherapies GmbH (Ltd.) have achieved great success in completely and permanently eliminating equine sarcoids and bovine papillomavirus that causes this aggressive form of skin cancer that horses often suffer from. By using its proprietary delNS technology, BlueSky Immunotherapies has created a viral vector ...
-
ROXALL Medizin acquires BIALs Allergene department
ROXALL Medizin in Hamburg and the Portuguese Pharma group BIAL have signed a contract. ROXALL takes over the allergy-section that, till now, was known as BIAL-Aristeguí. With this acquisition ROXALL provides the base for further growth. The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of ...
-
Creative Medical Technology to Participate in the 34th Annual Roth Conference
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that Company executives will be participating in the 34th Annual Roth Conference to be held March 13-15, 2022 in Dana Point, California. ...
-
Allovate Therapeutics Announces Issuance of U.S. Patent Covering Novel Oral Mucosal Immunotherapy Platform
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with ...
-
Allovate Therapeutics Appoints Bob Pomrenke as CEO
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
-
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® (tecovirimat) available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform ...
-
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. INT301 is a novel peanut desensitization immunotherapy formulated as ...
-
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, ...
-
Roswell Park introduces “Tactiva Therapeutics” as new Biotech Spinoff Company
BUFFALO, N.Y.(WKBW) – Lieutenant Governor Kathy Hochul, Dr. Candace Johnson and a special team of doctors at Roswell Park announced the launch of a new innovative Immunotherapy Biotech Company called, Tactiva Therapeutics in front of a packed house inside Roswell’s Research Center. Tactiva will develop the latest science to lead even more effective approaches at fighting and treating ...
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
New York, New York, November 10, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and ...
-
Imaxio and Centre Léon Bérard announce the execution of a collaboration agreement and the award of a grant for the preclinical development of an anticancer immunotherapy based on the Imaxio’s IMX313 technology
Imaxio, a biotech company specialized in immunology, announces today the execution of a collaboration agreement with Centre Léon Bérard, and the award of a grant, as part of the program “Proof of Concept CLARA” from the Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA), to finance the ORPhEE project. The ORPhEE project, “non-antigen specific ...
By IMAXIO S.A.
-
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today that it has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s PD-1 ...
-
Restore Health Selected To Provide Innovative Allergy Toothpaste System: Allerdent
Allovate, LLC, has signed an agreement with Restore Health, a company specializing in personalized medicine, for the exclusive rights to provide Allerdent™, a new personalized therapeutic toothpaste system for people suffering from allergic rhinitis. Allerdent™ is designed for daily use as part of a normal tooth-brushing regimen and enables allergy sufferers to incorporate ...
-
Allovate Therapeutics Provides Free Allerdent To Physicians
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of ...
-
LISCure Biosciences Has Completed Seed Funding of USD 5 Million for Bacteria-mediated Immunotherapy R&D Enhancement
LISCure Biosciences, a biotech company that researches and develops bacteria-mediated immunotherapy, has succeeded in attracting 5 million USD of seed funding investment. NHN Investment, Shinhan Investment, and KB Securities have participated in the financing, and LISCure is expected to strengthen its research and development capabilities of key technologies with the funds. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you